Nordson Corporation (NDSN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates stable to positive growth across segments, with notable strength in the medical and ATS segments. The Q&A reveals confidence in overcoming weather impacts and a strong order pipeline. Despite some margin challenges, management maintains a positive outlook with strong incrementals. The company's strategic focus on high-margin areas and disciplined M&A activity further supports a positive sentiment. Overall, the insights suggest a positive market reaction, likely within the 2% to 8% range.
Key Financial Performance
First Quarter Sales $669 million, a 9% increase over the prior year ($615 million). This reflects 7% overall organic growth, driven by robust demand in Asia and strength in the ATS segment, particularly in the semiconductor end market.
EBITDA $203 million, an 8% increase year-over-year. EBITDA margins were 30%, consistent with the prior year, despite geographic and product mix headwinds.
Adjusted Operating Profit $166 million, a 10% increase year-over-year. This was driven by increased SG&A leverage on organic sales growth and benefits from the divestiture of the medical contract manufacturing business.
Free Cash Flow $123 million, with a cash flow conversion rate over 100% of net income. This was achieved despite accelerated revenue growth.
Net Income $133 million or $2.38 per share. Adjusted earnings per share were $2.37, a 15% increase from the prior year's $2.06, reflecting solid operating leverage and benefits from the divested medical contract manufacturing business.
Industrial Precision Solutions Sales $327 million, a 9% increase year-over-year. Organic sales grew 3%, with a favorable currency impact of 6%. Growth was broad-based, with strength in Asia Pacific markets.
Medical and Fluid Solutions Sales $193 million, relatively flat year-over-year. Organic sales increased 3%, but divested sales from the medical contract manufacturing business negatively impacted by 4%. Winter storms caused a temporary 1% sales impact.
Advanced Technology Solutions Sales $149 million, a 23% increase year-over-year. Organic sales grew 21%, driven by semiconductor applications and recovering demand for X-ray systems. EBITDA increased 43% to $33 million, reflecting stronger sales volume and operational improvements.
Net Interest Expense $23 million, a decrease of $3 million year-over-year, due to lower debt levels and a stable to declining rate environment.
Other Income Increased $19 million year-over-year, primarily due to a $22 million non-cash gain from a minority investment's IPO on the Korean Stock Exchange.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Advanced Technology Solutions (ATS): Achieved over 20% growth compared to prior year, driven by semiconductor end market momentum. Semiconductor applications account for approximately 50% of ATS revenue, with strong demand for precision dispense applications and X-ray systems.
Medical and Fluid Solutions: Engineered fluid solutions product lines showed growth, driven by electronics and industrial applications. However, overall sales were flat due to divestiture impact.
Geographic Expansion: Strong demand in Asia across most end markets, particularly in advanced technology product lines for semiconductor applications.
Record Sales and Organic Growth: Achieved record first quarter sales of $669 million, a 9% increase over prior year, with 7% organic growth.
EBITDA and Margins: EBITDA increased 8% year-over-year to $203 million, maintaining 30% EBITDA margins despite geographic and product mix headwinds.
Cash Flow and Capital Deployment: Generated $123 million in free cash flow with over 100% cash flow conversion. Deployed capital for share repurchases, dividends, and strategic investments.
Semiconductor Focus: Investments in semiconductor applications, including advanced packaging processes and quality control systems, are driving growth. Positioned well in Asia Pacific and expanding geographically.
Divestiture Impact: Divested medical contract manufacturing business, which impacted sales but improved EBITDA margins in Medical and Fluid Solutions segment.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Geographic and Product Mix Challenges: Sales growth was concentrated in Asia, where gross margins are generally lower, particularly on system sales, leading to lower incremental leverage during the quarter.
Medical Segment Supply Chain Disruption: Winter storms at the end of January impacted production and medical supply chain, causing an estimated 1% impact on sales in the quarter.
Foreign Currency Fluctuations: Year-over-year changes in other income and expense were driven by foreign currency contract fluctuations, which could impact financial performance.
Market Demand Variability: Growth in general and automotive electronics markets remains muted, with only early signs of growing capacity needs in these end markets.
Potential Broader Market Pullback: The company is planning for a potential broader pullback in end market demand in the second half of the year, despite no current signs of this scenario.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Second Quarter Fiscal 2026 Sales: Expected to be in the range of $710 million to $740 million.
Second Quarter Adjusted Earnings: Forecasted to be in the range of $2.70 to $2.90 per diluted share.
Full Year Fiscal 2026 Sales: Expected in the range of $2.860 billion to $2.980 billion, representing an increase of 4.5% at the midpoint.
Full Year Adjusted Earnings: Projected to be in the range of $11 to $11.60 per diluted share, reflecting a 10% increase at the midpoint.
Semiconductor Segment Growth: Semiconductor applications, accounting for approximately 50% of ATS segment revenue, are expected to continue driving double-digit organic growth, supported by investments in Asia Pacific and potential growth in other regions.
Medical End Markets: Expected to return to normalized growth throughout the year, with benefits continuing to materialize.
Automotive and Polymer Processing Applications: Stabilized and expected to sustain growth.
Electronics and Industrial Applications: Driving growth in engineered fluid solution product lines.
X-ray Systems: Demand is starting to inflect, supporting semiconductor packaging quality control.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends Paid: $46 million in dividends were paid to shareholders during the quarter.
Share Repurchase: $82 million worth of shares were repurchased on the open market during the quarter.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can we unpack the margin dynamics around the systems geographic mix and whether the mix will improve in the next few quarters?
A:Management noted strong incrementals in the medical business and normal incrementals in the ATS business, with mix challenges primarily in IPS. They emphasized no fundamental change in the margin outlook, maintaining a 40% incremental expectation and best-in-class EBITDA margins.
Q:Can you expand on the slow start in medical ex, weather issues, and confidence in business picking up?
A:Incrementals were strong, exceeding 50% when excluding the CDMO divestiture. Growth was slower due to a 1% weather impact, but management is confident in mid-single-digit growth for the year, supported by stabilized supply chains, strong order entry momentum, and a healthy pipeline of customer projects.
Q:Can you provide more context on the ATS segment, including dispense, T&I, and order trajectory?
A:Dispense businesses showed strong momentum due to investments in AI-driven chip manufacturing. T&I businesses, including X-ray and AMI, are seeing growth, with X-ray showing recovery and AMI coming off strong years. Management expects ATS to exceed mid-single-digit growth targets for the year.
Q:Can you discuss the IPS segment and its growth trajectory?
A:IPS returned to 3% organic growth, driven by packaging, product assembly, and Precision Ag in Europe and South America. Polymer processing and automotive markets are stable but not significantly recovering. Growth is primarily in Asia Pacific, with limited inflection in Europe and North America.
Q:Can you elaborate on the weather impact on the medical business and its normalized performance?
A:The weather impact was primarily on interventional products and fluid components, causing a 1% growth reduction. Normalized growth would have been 4% instead of 3% for the quarter.
Q:What is the status of M&A activity, multiples, and areas of focus?
A:Management is actively pursuing opportunities in medical components, test and inspection, and core industrial technologies. Multiples vary, but the company remains disciplined, focusing on differentiated businesses with strong margins and growth potential.
Q:What are the signs of life in general electronics within ATS?
A:Demand is stable at low growth levels, with early signs of high-end semiconductor investments trickling into lower-level electronics. Management sees potential future inflection but currently observes stable demand.
Q:Is there activity in packaged optics within ATS?
A:Yes, Nordson has products supporting optical module manufacturing and is beginning to see related orders.
Q:What is the impact of FX on ATS and IPS margins?
A:FX contributed to a 6% sales growth in IPS but with lower incrementals (25%-30%). The impact will lessen throughout the year as FX rates stabilize.
Q:What would drive the high end of full-year guidance?
A:Upside could come from inflection in general industrial and automotive demand, as well as continued strength in ATS demand. Medical growth is expected to remain stable.
Q:What is the exposure to DRAM pricing and its impact?
A:Nordson has limited exposure to DRAM pricing, but capacity additions in memory could benefit the company.
Q:What is the cycle for test and inspection within ATS, and is X-ray recovery a precursor for growth?
A:X-ray recovery is slower compared to dispense and acoustic emission businesses. Semi-related X-ray is performing well, while automotive exposure is flat. Automotive recovery could further boost X-ray performance.
Q:What are the expectations for MFS margins given tough comps?
A:MFS margins are sustainable around 37%, with reasonable incrementals expected. The divestiture in Q4 impacts year-over-year comparisons, but management focuses on growth at reasonable incrementals.
Q:What is the impact of AI demand on ATS and its long-term outlook?
A:AI-driven demand boosts ATS performance, but management remains cautious, expecting mid-single-digit growth through the cycle despite higher growth during upcycles.
Q:What drove IPS strength in Asia Pacific, and what is the regional growth outlook?
A:Growth in Asia Pacific is broad-based, driven by packaging, product assembly, and Precision Ag. Polymer and automotive markets have stabilized, contributing to improved comps.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on win rates in ATS, citing internal policies. They also used general terms like 'balanced and prudent' when discussing full-year guidance, without elaborating on specific end-market dynamics or potential risks.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Asia
Corporate Communications
Exchange
Fluid Solutions
Medical Fluid
Nordson Conference
Relations Corporate
Slide
Solutions sale
balance sheet
cash flow
contract manufacturing
currency
debt leverage
divestiture
dividend
end market
enterprise
facility
gain tax
income gain
leverage sale
line sale
market demand
offering
product line
product mix
sale benefit
sale increase
sale product
segment strength
semiconductor
share record
system sale
volume leverage
NDSN Transcript
Nordson Corporation (NDSN) Q2 2026 Earnings Call Transcript
Neutral5-21
Nordson Corporation (NDSN) Q1 2026 Earnings Call Transcript
Positive2-19
The earnings call summary indicates stable to positive growth across segments, with notable strength in the medical and ATS segments. The Q&A reveals confidence in overcoming weather impacts and a strong order pipeline. Despite some margin challenges, management maintains a positive outlook with strong incrementals. The company's strategic focus on high-margin areas and disciplined M&A activity further supports a positive sentiment. Overall, the insights suggest a positive market reaction, likely within the 2% to 8% range.
Empire Company Limited (EMP.A:CA) Q2 2026 Earnings Call Transcript
Positive12-11
The earnings call presents a positive outlook with 12.5% EPS growth and strategic initiatives like technology investments and disciplined cost management. The Q&A highlights a focus on profitability, e-commerce growth, and leveraging partnerships, despite avoiding specifics on e-commerce penetration. The company's commitment to share repurchases and operational improvements further supports a positive sentiment. However, the lack of specific guidance on e-commerce penetration and current performance ratings introduces some uncertainty. Overall, the strategic focus and financial health suggest a positive stock price movement.
Nordson Corporation (NDSN) Q4 2025 Earnings Call Transcript
Positive12-11
The earnings call summary and Q&A indicate a positive outlook with strong operational execution, margin maintenance, and share repurchase plans. Despite some uncertainties, guidance suggests improvement, especially in the IPS and ATS segments. The company's capital deployment strategy and healthy growth drivers in medical and technology segments further bolster positive sentiment. While there are challenges, the overall sentiment leans towards a positive stock price movement over the next two weeks.
NDSN Slides
NDSN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
